Loading patent…
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsKenneth A. Jacobson, Heaok Kim Jeong, Suhaib M. Siddiqi, Carl R. Johnson, John A. Secrist, III, Kamal N. Tiwari
Estimating the term…
The present invention provides A.sub.3 selective agonists, particularly, adenine compounds having selected substituents at the 2, 6, and 9 positions, and related substituted compounds, particularly those containing substituents on the benzyl and/or uronamide groups, as well as pharmaceutical compositions containing such compounds. The present invention also provides a method of selectively activating an A.sub.3 adenosine receptor in a mammal, which method comprises acutely or chronically administering to a mammal in need of selective activation of its A.sub.3 adenosine receptor a therapeutically or prophylactically effective amount of a compound which binds with the A.sub.3 receptor so as to stimulate an A.sub.3 receptor-dependent response.
A compound of the formula:
A compound of the formula:
A compound of the formula:
A compound of the formula ##STR22## wherein R.sub.1 is ##STR23## wherein X.sub.1 is hydrogen or C.sub.1 -C.sub.10 hydroxyalkyl, X.sub.2 and X.sub.3 are independently hydrogen, hydroxyl, or halo, R.sub.2 is hydrogen or halo, and R.sub.3 is hydrogen, benzyl, or halobenzyl.
Dependencies are inferred from the claim text.